← Back to Clinical Trials
Recruiting NCT07699861

NCT07699861 LUCINAE Registry: Thoracic Cancers During Pregnancy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07699861
Status Recruiting
Phase
Sponsor Oncology Institute of Southern Switzerland
Condition Lung Cancer
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2026-06
Primary Completion 2035-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2026-06 with a primary completion date of 2035-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives. Because thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers. The results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.

Eligibility Criteria

Inclusion Criteria: * 1\. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including: 1. Patients receiving a diagnosis of thoracic cancer during pregnancy 2. Patients who became pregnant while having active thoracic cancer 3. Patients previously treated for a thoracic cancer and becoming pregnant in the 5 years following end of treatment OR Men with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities), who were undergoing active oncological treatment at the time their partner conceived their child. * 2\. Available information about pregnancy outcomes * 3\. Age ≥ 18 years Exclusion Criteria: * 1\. Patient missing data about thoracic cancer stage and diagnosis * 2\. For retrospective patients, documented refusal to the use of clinical data for research purposes

Contact & Investigator

Central Contact

Martina Imbimbo

✉ Martina.Imbimbo@eoc.ch

📞 +41918119631

Frequently Asked Questions

Who can join the NCT07699861 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07699861 currently recruiting?

Yes, NCT07699861 is actively recruiting participants. Contact the research team at Martina.Imbimbo@eoc.ch for enrollment information.

Where is the NCT07699861 trial being conducted?

This trial is being conducted at Baden, Switzerland, Bellinzona, Switzerland, Geneva, Switzerland, Winterthur, Switzerland.

Who is sponsoring the NCT07699861 clinical trial?

NCT07699861 is sponsored by Oncology Institute of Southern Switzerland. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology